Medpace Holdings Inc vs S&P500 ETF — how do they compare? Medpace Holdings Inc trades at $532.42 (market cap $15.08B), while S&P500 ETF trades at $748.25. The key difference: S&P500 ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | SPY | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | — |
52-Week High | $620.59 | $759.55 |
52-Week Low | $308.88 | $621.75 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
SPY trades at $742.21, down 0.13% with a bearish technical outlook. The S&P 500 index faces pressure, declining 1.6% last week and trading below its 50-day moving average. Recent news highlights concerns about market concentration in tech stocks and elevated valuations, though some analysts see potential for continued gains. A dividend of $1.90 is scheduled for July 2026.
The ETF's outlook is mixed amid technical weakness and valuation debates. While earnings season shows strength, market concentration and fee comparisons with sister funds present risks. The bearish technical signal suggests near-term caution, though long-term index exposure remains a core portfolio strategy for many investors.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →